Xeris Pharmaceuticals Operating Margin vs. Return On Asset
| XERS Stock | USD 3.42 0.04 1.18% |
Xeris Pharmaceuticals Operating Profit Margin |
|
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.91 | 0.8252 |
|
|
For Xeris Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Xeris Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Xeris Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Xeris Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Xeris Pharmaceuticals over time as well as its relative position and ranking within its peers.
Xeris |
Xeris Pharmaceuticals' Revenue Breakdown by Earning Segment
Check out Your Current Watchlist.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xeris Pharmaceuticals. If investors know Xeris will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xeris Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.43) | Revenue Per Share 1.301 | Quarterly Revenue Growth 0.123 | Return On Assets (0.09) | Return On Equity (6.17) |
The market value of Xeris Pharmaceuticals is measured differently than its book value, which is the value of Xeris that is recorded on the company's balance sheet. Investors also form their own opinion of Xeris Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Xeris Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xeris Pharmaceuticals' market value can be influenced by many factors that don't directly affect Xeris Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xeris Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xeris Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xeris Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Xeris Pharmaceuticals Return On Asset vs. Operating Margin Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Xeris Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Xeris Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Xeris Pharmaceuticals is rated fourth in operating margin category among its peers. It is rated third in return on asset category among its peers . At this time, Xeris Pharmaceuticals' Operating Profit Margin is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Xeris Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Xeris Return On Asset vs. Operating Margin
Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Xeris Pharmaceuticals |
| = | (0.24) % |
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Xeris Pharmaceuticals |
| = | -0.087 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Xeris Return On Asset Comparison
Xeris Pharmaceuticals is currently under evaluation in return on asset category among its peers.
Xeris Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Xeris Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Xeris Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Xeris Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Xeris Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -25 K | -26.2 K | |
| Net Interest Income | -21.9 M | -20.8 M | |
| Interest Income | 4.8 M | 5 M | |
| Operating Income | -44 M | -46.2 M | |
| Net Loss | -62.3 M | -65.4 M | |
| Income Before Tax | -63.5 M | -66.7 M | |
| Total Other Income Expense Net | -19.5 M | -18.5 M | |
| Net Loss | -85.2 M | -89.5 M | |
| Net Loss | -62.3 M | -65.4 M | |
| Income Tax Expense | -1.2 M | -1.2 M | |
| Non Operating Income Net Other | -6.9 M | -7.3 M | |
| Change To Netincome | 14.6 M | 15.3 M | |
| Net Loss | (0.45) | (0.47) | |
| Income Quality | 0.76 | 1.06 | |
| Net Income Per E B T | 0.98 | 1.09 |
Xeris Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Xeris Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Xeris Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Xeris Pharmaceuticals' important profitability drivers and their relationship over time.
Use Xeris Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Xeris Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Xeris Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Xeris Pharmaceuticals Pair Trading
Xeris Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Xeris Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Xeris Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Xeris Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Xeris Pharmaceuticals to buy it.
The correlation of Xeris Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Xeris Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Xeris Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Xeris Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Xeris Pharmaceuticals position
In addition to having Xeris Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Banking Thematic Idea Now
Banking
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Banking theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Banking Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Xeris Stock Analysis
When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.